For a patient who has had a myocardial infarction treated with percutaneous coronary intervention, how long should dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) be continued?

Duration of DAPT After PCI and MI

In patients with myocardial infarction treated with PCI, dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) should be continued for at least 12 months as the default strategy, with ticagrelor or prasugrel preferred over clopidogrel. 1, 2, 1, 3, 4

Standard Recommendation: 12 Months DAPT

The most recent ACC/AHA guidelines (2025) and established 2016 DAPT guidelines consistently recommend:

• Minimum duration: 12 months of aspirin (81 mg daily) plus a P2Y12 inhibitor for all ACS patients after PCI 1, 2, 1, 3, 4
• P2Y12 inhibitor choice hierarchy:
  • First-line: Ticagrelor (90 mg twice daily) or prasugrel (10 mg daily) 1, 2, 1, 3
  • Second-line: Clopidogrel (75 mg daily) only when ticagrelor/prasugrel unavailable or contraindicated 1, 2, 1
  • Contraindication: Prasugrel should NOT be used in patients with prior stroke/TIA 1, 2, 1

This applies to both STEMI and NSTE-ACS patients, regardless of stent type (BMS or DES) 1, 2, 1.

Strategies to Reduce Bleeding Risk

Early Aspirin Discontinuation (1-3 Months)

For patients who tolerate initial DAPT without bleeding complications, transitioning to P2Y12 inhibitor monotherapy after 1-3 months is reasonable to reduce bleeding risk 5, 3, 4:

• Ticagrelor monotherapy strategy: The 2025 ACC/AHA guidelines specifically recommend transitioning to ticagrelor monotherapy ≥1 month after PCI in patients who have tolerated DAPT 3, 4
• Bleeding reduction: This strategy significantly reduces major bleeding (OR 0.46 for ≤1 month discontinuation) and net adverse clinical events without increasing MACE 6, 7
• Important caveat: Very early aspirin discontinuation (<1 month) may increase stent thrombosis risk, particularly in higher ischemic risk ACS patients 7

High Bleeding Risk Patients

In patients who develop high bleeding risk or significant bleeding on DAPT, discontinuation of P2Y12 inhibitor after 6 months may be reasonable 1, 2, 1:

• High bleeding risk includes: prior bleeding on DAPT, need for oral anticoagulation, major intracranial surgery, coagulopathy 1, 2, 1
• European guidelines (2019) support 6-month DAPT in high bleeding risk patients (PRECISE-DAPT score ≥25) 8

Extended DAPT Beyond 12 Months

Continuation of DAPT beyond 12 months may be reasonable in selected patients who:

• Have tolerated DAPT without bleeding complications 1, 2, 1
• Are NOT at high bleeding risk 1, 2, 1
• Have high ischemic risk (prior MI, multivessel disease, diabetes, chronic kidney disease) 1, 2, 1

This is a Class IIb recommendation (may be reasonable), reflecting weaker evidence and requiring careful individualization 1, 2, 1.

Patients Requiring Anticoagulation

For patients requiring long-term anticoagulation, aspirin should be discontinued 1-4 weeks after PCI with continued P2Y12 inhibitor (preferably clopidogrel) 3, 4. This triple therapy duration minimization reduces bleeding while maintaining thrombotic protection.

Algorithm for Decision-Making

1. Start: All MI patients post-PCI receive aspirin + P2Y12 inhibitor (ticagrelor or prasugrel preferred)
2. At 1 month: Assess bleeding tolerance
   • If tolerated well → Consider transition to ticagrelor monotherapy 3, 4
   • If high bleeding risk develops → Continue DAPT to 6 months minimum 1, 2, 1
3. At 6 months: Reassess
   • High bleeding risk patients → May stop P2Y12 inhibitor 1, 2, 1
   • Standard risk → Continue to 12 months 1, 2, 1
4. At 12 months: Reassess ischemic vs bleeding risk
   • High ischemic risk + low bleeding risk → Consider extending DAPT 1, 2, 1
   • Otherwise → Transition to aspirin monotherapy 1, 2, 1

Key Pitfalls to Avoid

• Do not use clopidogrel as first-line when ticagrelor or prasugrel are available 1, 2, 1, 3
• Do not give prasugrel to patients with prior stroke/TIA 1, 2, 1
• Do not stop DAPT prematurely (<6 months) without compelling bleeding indication 1, 2, 1
• Do not extend DAPT indefinitely without reassessing bleeding risk 1, 2, 1
• Do not forget proton pump inhibitor in patients at GI bleeding risk on DAPT 3, 4

The 2025 guidelines represent a shift toward earlier aspirin discontinuation strategies based on emerging evidence showing net clinical benefit from reduced bleeding without compromising ischemic protection 3, 4, 6, 7.